Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Here's what you need to know about the new Omicron boosters. - The Boston Globe

The COV-BOOST Trial: Safety and Immunogenicity of Boosters - REBEL EM - Emergency Medicine Blog

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era - ScienceDirect

Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity - Mucosal Immunology

Dean Huang's Instagram, Twitter & Facebook on IDCrawl

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Frontiers Viral vector and nucleic acid vaccines against COVID-19: A narrative review

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants - ScienceDirect

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans